Strategic Collaboration to Address Critical Healthcare Needs and Expand Access to Life-Changing Treatments Riyadh – Tabuk Pharmaceutical Manufacturing Company (a fully owned subsidiary of Astra Industrial Group), a leading Saudi pharmaceutical company, today announced an exclusive licensing agreement with Polaris, a…
Tabuk Pharmaceuticals Expands Strategic Partnership with HK inno.N to Include Additional MENA Markets for K-CAB® (Tegoprazan)
Riyadh, Saudi Arabia – [May 7 2025] — Tabuk Pharmaceuticals, a leading Saudi pharmaceutical company with a strong regional footprint across the Middle East and North Africa (MENA), announced today the expansion of its strategic collaboration with HK inno.N for the…
Tabuk Pharmaceuticals Partners with Bio-Thera Solutions forRights to Manufacture and Commercialize BAT2206,a Stelara® (Ustekinumab) Biosimilar in Saudi Arabia
Manufacturing Company (a fully-owned subsidiary of Astra Industrial Group), a leading pharmaceutical company in the Middle East and North Africa (MENA) region, today announced the signing of a license, manufacturing, supply and commercialization agreement with Bio-Thera Solutions Inc. (688177:SH), a commercial-stage…
TABUK AND HK INNO.N PARTNER TO BRING K-CAB® (TEGOPRAZAN) AN INNOVATIVE MEDICINE TO THE MENA REGION.
Riyadh – Tabuk Pharmaceutical Manufacturing Company (a fully owned subsidiary of Astra Industrial Group), a leading Saudi pharmaceuticals company, announced today an exclusive license agreement with HK inno.N, a leading Korean pharmaceuticals company, to commercialize Tegoprazan, a novel potassium-competitive acid blocker…